Camurus announced positive study results for its subcutaneous buprenorphine depot injections (Buvidal) for treating opioid dependence.
Lund, Sweden-based Camurus’ 24-week, randomized, controlled trial compared patient-reported outcomes of opioid dependence treatment with subcutaneous weekly and monthly Buvidal depot injections against daily sublingual buprenorphine. Results were published in JAMA Network Open yesterday.
Get the full story at our sister site, Drug Delivery Business News.